Ariel Katz On Raising $70 Million To Arm Healthcare With Live Insights
Ariel Katz is the cofounder and CEO of H1 which develops a healthcare data analytics platform intended to help companies make smarter scientific decisions. The company has raised over $70 million from top tier investors such as Menlo Ventures, IVP, Lux Capital, Lux Capital, Liquid 2 Ventures, and Lead Edge Capital to name a few.
Today's guest is Ariel Katz, CEO & Co-Founder at H1 in New York. H1 is the first company to arm healthcare and life science companies with on-demand, live insights from across the data universe to accelerate the discovery and development of therapies to fight diseases. Their mission is to create a healthier future and is doing so by delivering a platform that connects stakeholders across the healthcare ecosystem for greater collaboration and discovery. H1 provides real-time data to support the end-to-end therapeutic development process from fundraising to product development to product launch, helping companies make smarter scientific decisions. Working with medical affairs and strategy teams who span all phases of the development lifecycle, they provide the complete picture of institutions, experts, scholarly content, markets, competitors and new opportunities through research grounded in actual data and clinical findings. In the show, Ariel will chat about: His journey to co-founding H1, Challenges they overcame to make H1 what it is today, Use cases of the benefits their platform bring to clients in the Healthcare industry, How they are applying Data Science and Machine Learning, What he enjoys about working within startups, How he went about building a successful team, & Plans for the future at H1
#6 - Building Healthcare's Connective Data Ecosystem w/ Ariel Katz
Ariel Katz is the Co-founder and CEO of H1 Insight, a network dedicated to connecting healthcare professionals and companies with the aims of being the "Linkedin for healthcare."Founded in 2017, H1 now has over 8 million HCP profiles in 16,000 institutions in 70-plus countries. Its clients, which encompass over 35 pharmaceutical companies, including seven of the top 10, use the platform to do things like find doctors to work on a clinical trial for a given biotech, find hospitals where they can do their clinical and find the thought leading healthcare professional to lead a CME session. H1 saw its revenue grew 350 percent year-to-year in 2019.The company, which graduated from Y Combinator, recently raised it first institutional funding round, a $12.9 million Series A led by Menlo Ventures, along with Novartis dRx, Y Combinator, Baron Davis Enterprises, ClearPoint Investment Partners, Jeff Hammerbacher, Liquid 2 Ventures, and Underscore VC.
Episode 50: Ariel Katz on the Long-Awaited York University v. Access Copyright Ruling
The Federal Court of Appeal delivered its long-awaited copyright ruling in the York University v. Access Copyright case last month which effectively confirms that educational institutions can opt-out of the Access Copyright licence since it is not mandatory and that any claims of infringement will be left to copyright owners to address, not Access Copyright. The decision also represents a major validation for University of Toronto law professor Ariel Katz, whose research and publications, which made the convincing case that a ‘mandatory tariff’ lacks any basis in law”, was directly acknowledged by the court and played a huge role in its analysis. Professor Katz joins me on the podcast this week to talk about the case, the role of collective licensing in copyright law, and what might come next for a case that may force Access Copyright to rethink the value proposition of its licence.
About this episode:Ariel is the co-founder and CEO of H1. H1 is building tools for medical affairs organizations to identify, analyze and apply the critical information surrounding opinion leaders to their engagements. Listen to this episode if you are interested in:- HealthTech- Hiring after product-market fit- Work-life balance - Knowing what to work on- Business strategy- And tons more!★ Support this podcast ★